Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N7/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/011032METHOD OF PRODUCING MODIFIED VIRUS GENOMES AND PRODUCING MODIFIED VIRUSES
WO 13.01.2022
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/US2021/040716 Applicant CODAGENIX INC. Inventor COLEMAN, John Robert
The present invention describes methods of generating a modified viral genome, producing infectious RNA, and generating modified viruses. The modified viral genome, infections RNA, and modified viruses comprise deoptimized nucleic acids; for example, codon-pair deoptimized or synonymous codon deoptimized. These modified viruses can be used in vaccines and methods of eliciting a protective immune response.
2.WO/2022/007742RECOMBINANT PSEUDORABIES VIRUS AND VACCINE COMPOSITION THEREOF
WO 13.01.2022
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CN2021/104472 Applicant NOVO BIOTECH CORP. Inventor ZHANG, Qiang
Provided is a recombinant pseudorabies virus having a genome containing nucleotide sequence encoding capsid protein P72, accessory protein B602L, and outer envelope protein CD2V derived from African swine fever virus. The recombinant pseudorabies virus can be used to prepare a live virus vector vaccine for effectively treating or preventing African swine fever, thereby overcoming the shortcomings of the existing inactivated vaccines and live attenuated vaccines.
3.WO/2022/007802T LYMPHOCYTE AND APPLICATION THEREOF
WO 13.01.2022
Int.Class C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
Appl.No PCT/CN2021/104799 Applicant SHENZHEN FEIPENG BIOLOGICAL THERAPY CO., LTD. Inventor DU, Xiaolong
Provided is a T lymphocyte. The T lymphocyte expresses a chimeric antigen receptor, and comprises an extracellular region. The extracellular region comprises a first single-chain antibody, a second single-chain antibody, a first linker peptide, and a CD8 hinge region. The first linker peptide is provided between the first single-chain antibody and the second single-chain antibody. The first single-chain antibody comprises a first heavy chain variable region, a first light chain variable region, and a second linker peptide. The second linker peptide is provided between the first heavy chain variable region and the first light chain variable region. The second single-chain antibody comprises a second heavy chain variable region, a second light chain variable region, and a third linker peptide. The third linker peptide is provided between the second heavy chain variable region and the second light chain variable region. The first linker peptide has a repeated amino acid sequence of GGGGS, and the second linker peptide and the third linker peptide independently have 2-6 repeated amino acid sequencse of GGGGS, respectively.
4.20220010288PROTEIN-BASED PURIFICATION MATRICES AND METHODS OF USING THE SAME
US 13.01.2022
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No 17493938 Applicant Isolere Bio, Inc. Inventor Kelli M. LUGINBUHL

Provided herein are protein-based purification matrices and methods of use thereof to purify biologics and/or to remove contaminants from a composition. Methods of bringing two or more biologics in close proximity are also provided. The disclosed compositions and methods allow for faster, more efficient purification of a biologic compared to traditional affinity chromatography.

5.20220008532MULTIVALENT FELINE VACCINE
US 13.01.2022
Int.Class A61K 39/295
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
Appl.No 17488961 Applicant Intervet Inc. Inventor Zhichang Xu

The present invention provides new multivalent vaccines for felines. The present invention also provides methods of making and using the multivalent vaccines alone or in combinations with other protective agents.

6.20220009970IMMUNOGENIC COMPOSITION AGAINST AVIAN INFLUENZA VIRUS H5 SUBTYPE
US 13.01.2022
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No 17291924 Applicant BOEHRINGER INGELHEIM VETMEDICA GMBH Inventor Egbert Siegfried MUNDT

The invention relates to the field of veterinary medicine. The invention provides an immunogenic composition, comprising a hemagglutinin protein of avian influenza virus H5 subtype. Also provided is a method of differentiating animals naturally infected with AIV from animals vaccinated with the immunogenic composition of the invention. The immunogenic composition of the invention can provide a broader, more effective, long-lasting and early onset protection on poultry.

7.WO/2022/008700PROCESS FOR PRODUCING A PURIFIED RHABDOVIRUS FROM CELL CULTURE
WO 13.01.2022
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/EP2021/069091 Applicant BOEHRINGER INGELHEIM INTERNATIONAL GMBH Inventor MUELLER, Dethardt
The present invention relates to the field of upstream and downstream processing and provides a process for producing a purified rhabdovirus from a cell culture, preferably a purified oncolytic rhabdovirus and in particular a vesicular stomatitis virus, including pharmaceutical compositions comprising the rhabdovirus.
8.20220010284SYSTEM FOR PROTEIN INACTIVATION AND RECOMBINANT PHAGES FOR TARGETED BACTERIAL KILLING, INFECTION, BIODETECTION, AND AS A MEANS OF PROTEIN EXTRACTION
US 13.01.2022
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No 17289336 Applicant The Trustees of Princeton University Inventor Justin E. Silpe

Disclosed are recombinant phages that infect and kill bacterial hosts in response to user-defined inputs. The components that encode the user-defined inputs can be combined, such that multiple inputs are maintained on a single recombinant phage, enabling precise control over the targeting strategy. The phages can be engineered to kill a specific bacterial species or multiple species simultaneously. Recombinant phages can also be engineered to harbor fluorescent and bioluminescent reporter genes that enable them to be used for tracking, detection, and in biosensing applications. Recombinant phages can also be used to lyse bacterial cells that produce recombinant proteins, as a rapid method to enable extraction and high-level purification of potentially valuable and/or industrially important proteins. Also disclosed is a system that can also be used to control the activity of a protein of interest, by taking advantage of an interaction between Qtip and a phage repressor protein; a phage repressor protein can be fused to a protein-of-interest, and by controlling the expression of qtip, the phage repressor protein fused to a protein-of-interest will be inactivated when Qtip is expressed and interacts with the phage repressor protein.

9.WO/2022/011082COMPOSITIONS AND METHODS FOR PRODUCING SINGLE STRANDED DNA
WO 13.01.2022
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/US2021/040792 Applicant STELLATE BIOTHERAPEUTICS, INC. Inventor HUH, Jin Hang
An isolated nucleic acid includes a first sequence from a filamentous bacteriophage, the first sequence having both initiator and terminator functions; a second sequence that is identical to the first sequence; and a single-strand DNA sequence of interest that is located between the first sequence and the second sequence. A host cell including the isolated nucleic acid and a method for producing a single-stranded DNA are also disclosed.
10.WO/2022/010213METHOD FOR PRODUCTION OF VARICELLA ZOSTER VIRUS SURFACE PROTEIN ANTIGEN
WO 13.01.2022
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/KR2021/008537 Applicant GREEN CROSS CORPORATION Inventor LEE, Kwang Bae
The present invention relates to a method for production of a varicella zoster virus surface protein antigen. The method for production of a varicella zoster virus surface protein antigen according to the present invention is an effective production method by which a varicella zoster surface protein antigen can be obtained at high yield and purity. Therefore, the method is advantageous for producing a surface protein antigen of varicella zoster virus for use as a vaccine composition for prevention or treatment of chicken pox or herpes zoster.